SG11201810927QA - Pd-l1-specific antibodies and methods of using the same - Google Patents

Pd-l1-specific antibodies and methods of using the same

Info

Publication number
SG11201810927QA
SG11201810927QA SG11201810927QA SG11201810927QA SG11201810927QA SG 11201810927Q A SG11201810927Q A SG 11201810927QA SG 11201810927Q A SG11201810927Q A SG 11201810927QA SG 11201810927Q A SG11201810927Q A SG 11201810927QA SG 11201810927Q A SG11201810927Q A SG 11201810927QA
Authority
SG
Singapore
Prior art keywords
international
control mab
pct
antibodies
fragments
Prior art date
Application number
SG11201810927QA
Inventor
Jonathan Belk
Nathan Sharkey
Leonid Gorelik
Original Assignee
Checkpoint Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Checkpoint Therapeutics Inc filed Critical Checkpoint Therapeutics Inc
Publication of SG11201810927QA publication Critical patent/SG11201810927QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

CTINegative control mAb Clinical control mAb IC50 0.4909 0.1941 - 0.0 60000 40000 20000 0 0.001 0.01 0.1 1 10 I ogiAntagonisq, ugeml -J 100 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 January 2018 (04.01.2018) W I PO I PCT mu °million °nolo olon imio (10) International Publication Number WO 2018/005682 A2 (51) International Patent Classification: C07K 16/28 (2006.01) A61K 45/06 (2006.01) (21) International Application Number: PCT/US2017/039810 (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: without international search report and to be republished upon receipt of that report (Rule 48.2(g)) 28 June 2017 (28.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/356,105 29 June 2016 (29.06.2016) US (71) Applicant: CHECKPOINT THERAPEUTICS, INC. [US/US]; 2 Gansevoort Street, 9th Floor, New York, NY 10014 (US). (72) Inventors: BELK, Jonathan; c/o Adimab, LLC, 7 Lucent Drive, Lebanon, NH 03766 (US). SHARKEY, Nathan, J.; c/o Adimab, LLC, 7 Lucent Drive, Lebanon, NH 03766 (US). GORELIK, Leonid; 69 Winston Road, Newton, MA 02459 (US). (74) Agent: VILLACORTA, Gilberto, M. et al.; Foley & Lard- ner LLP, 3000 K Street NW, Suite 600, Washington, DC 20007 (US). = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, W O 20 18/005 68 2 A2 (54) Title: PD-Ll-SPECIFIC ANTIBODIES AND METHODS OF USING THE SAME is Clinical control mAb CTI-048 A Negative control mAb FIGURE 5 (57) : The present disclosure relates generally to antibodies and functional binding fragments thereof that bind to programmed death-ligand 1 (PD-L1). In particular, the disclosed antibodies and fragments bind to human PD-Ll and comprise novel complementary determining regions (CDRs) also disclosed herein. Finally, the present disclosure relates to administering the disclosed antibodies and fragments to subjects with cancer, thereby treating or slowing the progression or proliferation of the cancer.
SG11201810927QA 2016-06-29 2017-06-28 Pd-l1-specific antibodies and methods of using the same SG11201810927QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662356105P 2016-06-29 2016-06-29
PCT/US2017/039810 WO2018005682A2 (en) 2016-06-29 2017-06-28 Pd-l1-specific antibodies and methods of using the same

Publications (1)

Publication Number Publication Date
SG11201810927QA true SG11201810927QA (en) 2019-01-30

Family

ID=60785529

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201810927QA SG11201810927QA (en) 2016-06-29 2017-06-28 Pd-l1-specific antibodies and methods of using the same
SG10202100100UA SG10202100100UA (en) 2016-06-29 2017-06-28 Pd-l1-specific antibodies and methods of using the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202100100UA SG10202100100UA (en) 2016-06-29 2017-06-28 Pd-l1-specific antibodies and methods of using the same

Country Status (13)

Country Link
US (2) US10590199B2 (en)
EP (1) EP3478723A4 (en)
JP (2) JP7148414B2 (en)
KR (2) KR20190028716A (en)
CN (1) CN109641960A (en)
AU (1) AU2017290709A1 (en)
BR (1) BR112018076684A2 (en)
CA (1) CA3027204A1 (en)
IL (2) IL263611B (en)
MX (1) MX2018016183A (en)
RU (1) RU2749109C2 (en)
SG (2) SG11201810927QA (en)
WO (1) WO2018005682A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CN108112254B (en) 2015-03-13 2022-01-28 西托姆克斯治疗公司 anti-PDL 1 antibodies, activatable anti-PDL 1 antibodies, and methods of use thereof
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
JP7148414B2 (en) * 2016-06-29 2022-10-05 チェックポイント セラピューティクス，インコーポレイテッド PD-L1 specific antibodies and methods of using same
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
KR20200016899A (en) 2017-06-01 2020-02-17 싸이톰스 테라퓨틱스, 인크. Activatable anti-PDL1 antibody, and methods of using the same
IL296408A (en) * 2018-10-31 2022-11-01 Immunitybio Inc Elimination of pd-l1-positive malignancies by pd-l1 chimeric antigen receptor-expressing nk cells
KR102207478B1 (en) * 2019-03-13 2021-01-26 한국도로공사 Tolling system using time information and operating method thereof
WO2020216379A1 (en) * 2019-04-26 2020-10-29 I-Mab Human pd-l1 antibodies
EP3976090A1 (en) 2019-05-24 2022-04-06 Pfizer Inc. Combination therapies using cdk inhibitors
CN113121686A (en) * 2019-12-31 2021-07-16 迈威(上海)生物科技股份有限公司 anti-PD-L1 antibody and application thereof
WO2023057882A1 (en) 2021-10-05 2023-04-13 Pfizer Inc. Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
EP1907421A4 (en) * 2005-06-30 2012-03-28 Abbott Lab Il-12/p40 binding proteins
CN101248089A (en) * 2005-07-01 2008-08-20 米德列斯公司 Human monoclonal antibodies to programmed death ligand 1(PD-L1)
AU2006308648A1 (en) 2005-10-31 2007-05-10 Duke University Antibodies and immunotoxins that target human glycoprotein NMB
GB0914691D0 (en) 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants
NZ599405A (en) * 2009-11-24 2014-09-26 Medimmune Ltd Targeted binding agents against b7-h1
AU2012344260B2 (en) * 2011-11-28 2017-09-07 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
KR102163408B1 (en) * 2012-05-31 2020-10-08 소렌토 쎄라퓨틱스, 인코포레이티드 Antigen binding proteins that bind pd-l1
KR101947702B1 (en) * 2012-10-04 2019-02-14 다나-파버 캔서 인스티튜트 인크. Human monoclonal anti-pd-l1 antibodies and methods of use
TWI680138B (en) * 2014-01-23 2019-12-21 美商再生元醫藥公司 Human antibodies to pd-l1
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
CA2968412A1 (en) * 2014-12-19 2016-06-23 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptors and methods of use thereof
CN108112254B (en) * 2015-03-13 2022-01-28 西托姆克斯治疗公司 anti-PDL 1 antibodies, activatable anti-PDL 1 antibodies, and methods of use thereof
US10501551B2 (en) * 2016-01-11 2019-12-10 Inhibrx, Inc. Multivalent and multispecific 41BB-binding fusion proteins
US10787518B2 (en) * 2016-06-14 2020-09-29 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
JP7148414B2 (en) * 2016-06-29 2022-10-05 チェックポイント セラピューティクス，インコーポレイテッド PD-L1 specific antibodies and methods of using same
US20190247399A1 (en) * 2016-09-09 2019-08-15 Tg Therapeutics, Inc. Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers

Also Published As

Publication number Publication date
IL263611A (en) 2019-01-31
EP3478723A2 (en) 2019-05-08
US11834505B2 (en) 2023-12-05
BR112018076684A2 (en) 2019-04-02
RU2749109C2 (en) 2021-06-04
JP7148414B2 (en) 2022-10-05
JP2019532013A (en) 2019-11-07
WO2018005682A3 (en) 2018-02-08
CA3027204A1 (en) 2018-01-04
US10590199B2 (en) 2020-03-17
CN109641960A (en) 2019-04-16
US20180002424A1 (en) 2018-01-04
JP2022120008A (en) 2022-08-17
IL263611B (en) 2020-08-31
KR20220004763A (en) 2022-01-11
SG10202100100UA (en) 2021-02-25
MX2018016183A (en) 2019-06-10
IL276515A (en) 2020-09-30
RU2019102009A3 (en) 2020-12-14
AU2017290709A1 (en) 2019-01-24
RU2019102009A (en) 2020-07-28
EP3478723A4 (en) 2020-07-29
US20200277380A1 (en) 2020-09-03
KR20190028716A (en) 2019-03-19
KR102422411B1 (en) 2022-07-18
WO2018005682A2 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201807176XA (en) TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201811432WA (en) Rna for cancer therapy
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201807982UA (en) Substituted inhibitors of menin-mll and methods of use
SG11201808196UA (en) Neoantigens and methods of their use
SG11201805422WA (en) Multivalent and multispecific ox40-binding fusion proteins
SG11201805420SA (en) Antibodies and conjugates thereof
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11202000105QA (en) Anti-cd166 antibodies and uses thereof
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201903835WA (en) Antibodies directed against programmed death- 1 (pd-1)
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201806251WA (en) Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201809751XA (en) Egfr inhibitor compounds